Kidder Stephen W cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,919 shares of the company’s stock after selling 1,815 shares during the quarter. Johnson & Johnson makes up about 5.1% of Kidder Stephen W’s investment portfolio, making the stock its largest position. Kidder Stephen W’s holdings in Johnson & Johnson were worth $13,902,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares during the last quarter. IHT Wealth Management LLC grew its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $124,000. Hedge funds and other institutional investors own 65.70% of the company’s stock.
A number of equities research analysts have recently weighed in on the company. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective on the stock. in a research report on Monday. JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. BMO Capital Markets lifted their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $145.52.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.68 EPS. analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is presently 58.33%.
COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/01/11/johnson-johnson-jnj-stake-lowered-by-kidder-stephen-w.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.